Sanofi receives marketing approval for its diabetes drug Soliqua™ in India • Pre-filled pens containing a combination of insulin glargine 100 Units/mL and lixisenatide for once-daily dosing  Mumbai, March 28, 2023. Sanofi (India) announced that it has received marketing authorization for its diabetes drug Soliqua™ (in pre-filled pen) from the Central Drugs Standard Control Organization (CDSCO). Soliqua™ is indicated as treatment to improve glycemic control as an adjunct to diet and exercise, in adults with obesity and type 2 diabetes who are insufficiently controlled on oral or injectable therapies. It comes in once daily dosing of pre-filled pens in fixed-ratio combination (10-40 and 30-60) of insulin glargine and lixisenatide.  
Visit http://educratsweb.com/3090-content.htm

---